Evotec AG / Key word(s): Miscellaneous
02.12.2014 18:04
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) announced today that it has entered into
exclusive negotiations with Sanofi on a major multi-component strategic
alliance over the next five years. The alliance, on completion, will cover
three major strategic initiatives:
Firstly, over the next five years, Evotec and Sanofi will collaborate on
pre-clinical development project initiatives with an initial focus on
oncology and Evotec will also license from Sanofi a portfolio of projects
including five well-advanced pre-clinical projects in oncology. Secondly,
Evotec and Sanofi will enter into an outsourcing alliance and Evotec will
acquire Sanofi's scientific operations in Toulouse, France. Evotec will
integrate these scientific operations including more than 200 highly
experienced scientists into its global drug discovery platform. From this
new facility, Evotec will perform collaborative research with its Pharma,
biotech and academic partners as well as internal research. Evotec will
also assume management of Sanofi's global screening library. Lastly, Evotec
and Sanofi will combine their compound libraries and make them available
for screening projects to Evotec's partners.
The collaboration will result in a minimum guaranteed commitment from
Sanofi to Evotec of EUR 250 m over the next five years, including a
sizeable upfront cash payment that will be defined in the agreement. Evotec
will also be entitled to milestone and royalty rights on some potential
products that will be generated within the joint discovery and pre-clinical
programmes.
This multi-component transaction is expected to be signed in the first half
of 2015, subject to finalization of definitive agreements and completion of
the appropriate social process.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-242, werner.lanthaler@evotec.com
02.12.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration
| Source: EQS Group AG